@article{9b21229286d2456f9d0e1eb3e3982a62,
title = "Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls",
abstract = "Background: Increased cancer risk has been reported in Parkinson's disease (PD) patients carrying the leucine rich repeat kinase 2 (LRRK2) G2019S mutation (LRRK2-PD) in comparison with idiopathic PD (IPD). It is unclear whether the elevated risk would be maintained when compared with unaffected controls. Methods: Cancer outcomes were compared among 257 LRRK2-PD patients, 712 IPD patients, and 218 controls recruited from 7 LRRK2 consortium centers using mixed-effects logistic regression. Data were then pooled with a previous study to examine cancer risk between 401 LRRK2-PD and 1946 IPD patients. Results: Although cancer prevalence was similar among LRRK2-PD patients (32.3%), IPD patients (27.5%), and controls (27.5%; P = 0.33), LRRK2-PD had increased risks of leukemia (odds ratio [OR] = 4.55; 95% confidence interval [CI], 1.46–10.61) and skin cancer (OR = 1.61; 95% CI, 1.09–2.37). In the pooled analysis, LRRK2-PD patients had also elevated risks of leukemia (OR = 9.84; 95% CI, 2.15–44.94) and colon cancer (OR = 2.34; 95% CI, 1.15–4.74) when compared with IPD patients. Conclusions: The increased risks of leukemia as well as skin and colon cancers among LRRK2-PD patients suggest that LRRK2 mutations heighten risks of certain cancers.",
keywords = "G2019S mutation, LRRK2 gene, Parkinson's disease, colon cancer, leukemia, pooled analysis",
author = "Ilir Agalliu and Ortega, {Roberto A.} and Luciano, {Marta San} and Anat Mirelman and Claustre Pont-Sunyer and Kathrin Brockmann and Dolores Vilas and Eduardo Tolosa and Daniela Berg and Bj{\o}rg War{\o} and Amanda Glickman and Deborah Raymond and Rivka Inzelberg and Javier Ruiz-Martinez and Elisabet Mondragon and Eitan Friedman and Sharon Hassin-Baer and Alcalay, {Roy N.} and Helen Mejia-Santana and Jan Aasly and Tatiana Foroud and Karen Marder and Nir Giladi and Susan Bressman and Rachel Saunders-Pullman",
note = "Funding Information: Ilir Agalliu and Rachel Saunders-Pullman had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. This work was supported by the Michael J. Fox Foundation, the Bigglesworth Family Foundation, and the National Institutes of Health/National Institute of Neurological Disorders and Stroke (Grants: NS073836 and NS094148 to R.S.P.). The funding agencies had no role in the design and conduct of the study; data collection, management, analysis, and interpretation of the data; as well as in preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication. Publisher Copyright: {\textcopyright} 2019 International Parkinson and Movement Disorder Society",
year = "2019",
month = sep,
day = "1",
doi = "10.1002/mds.27807",
language = "English (US)",
volume = "34",
pages = "1392--1398",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",
number = "9",
}
